ArticleCVIR endovascular2026
Fibrinogen monitoring does not significantly reduce rates of bleeding complications during catheter-directed thrombolysis.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of fibrinogen monitoring on bleeding complications and rates of premature tPA cessation in patients undergoing catheter-directed thrombolysis (CDT). We hypothesize that routine fibrinogen monitoring does not lower bleeding complications but may result in more cases of incomplete thrombolysis due to premature tPA termination.
methodsThis single-institution retrospective study examined patients who underwent CDT for arterial, venous, or pulmonary thrombosis from 2011 to 2023. Rates of significant hemorrhages and premature tPA cessation were compared in patients with and without routine fibrinogen monitoring. Premature tPA cessation was defined as termination of thrombolytic infusion prior to the planned treatment endpoint due to low fibrinogen levels or clinical bleeding concerns.
resultsA total of 355 CDT procedures met inclusion criteria, including 225 cases without routine monitoring (control group) and 130 with routine fibrinogen monitoring. Bleeding rates were similar between groups (3.55% vs. 3.07%, p = 1.00). However, premature tPA cessation occurred significantly more frequently in the fibrinogen monitoring cohort (17.5% vs. 1.78%, p < 0.001). Among cases with premature tPA cessation, residual thrombus requiring adjunctive interventions was common.
conclusionThis study demonstrated that routine fibrinogen monitoring was not associated with significantly reduced bleeding complications, but is linked to higher rates of premature tPA cessation in stable patients, which may contribute to incomplete thrombolysis and increased need for adjunctive interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.